secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allarity Therapeutics, Inc. (ALLR)
CIK:        0001860657
Form:       8-K
Filed at:   2025-09-22T23:59:59+00:00
Accession:  0001213900-25-089680
Event type: other_material
Sentiment:  neutral
Materiality: 0.20
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allarity CEO to present at Biomarkers & Precision Medicine 2025 in London on Oct 1
--------------------------------------------------------------------------------

- CEO Thomas Jensen invited to present at Oxford Global conference on October 1, 2025.
- Presentation title: 'A Gene Expression Based Biomarker For Predicting Response To Treatment With Stenoparib'.
- Jensen will also be interviewed by Oxford Global's editorial team for their online portal.
- Jensen available for one-on-one meetings during the conference to discuss business development.
- Allarity is a Phase 2 clinical-stage company developing dual PARP/WNT inhibitor stenoparib.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860657/000121390025089680/0001213900-25-089680-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860657/000121390025089680/ea0258005-8k_allarity.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-089680

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer